Physician profile
David Robles
NPI 1326156233
$11,961.04
in general payments reported to CMS, 2019-2025
30 companies · $1,700 in 2025
The $1,700 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,051 · 2020: $1,052 · 2021: $1,926 · 2022: $2,255 · 2023: $1,623 · 2024: $2,355 · 2025: $1,700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,498 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,498.19 |
| Education | $178.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,526.86 | 2020-2025 | |
| Abbvie INC. | $1,510.36 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Leo Pharma INC. | $1,432.15 | 2020-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $1,429.86 | 2020-2025 | Dupixent |
| Janssen Biotech, INC. | $1,302.33 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Ucb, INC. | $823.65 | 2019-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $645.44 | 2019-2025 | |
| Galderma Laboratories, L.P. | $479.74 | 2019-2025 | Nemluvio |
| Pfizer INC. | $475.77 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $457.95 | 2019-2025 | Absorica Ld, Winlevi |
| Lilly USA, LLC | $422.66 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $255.66 | 2022-2024 | Sotyktu |
| Incyte Corporation | $250.76 | 2021-2023 | Opzelura |
| Dermira, INC. | $164.12 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.65 | 2023-2024 | Cyltezo, Spevigo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $138.06 | 2019-2025 | Otezla, Otezla |
| Sanofi-Aventis U.S. LLC | $108.82 | 2020-2021 | |
| Dermavant Sciences, INC. | $93.14 | 2022-2024 | Vtama |
| Almirall LLC | $39.46 | 2019-2024 | Klisyri |
| Verrica Pharmaceuticals INC. | $39.32 | 2024 | Ycanth |
| Mayne Pharma Commercial LLC | $37.05 | 2019-2023 | |
| Bard Peripheral Vascular, INC. | $33.87 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $33.24 | 2019 | |
| Kyowa Kirin, INC. | $24.68 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $23.92 | 2023 | Evusheld |
| Helsinn Therapeutics (U.S.), INC. | $16.69 | 2021 | |
| Biofrontera INC. | $15.92 | 2020 | |
| Zimmer Biomet Holdings, INC. | $14.74 | 2020 | |
| Nabriva Therapeutics, Plc | $13.32 | 2022 | |
| Icad, INC | $11.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Robles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.